Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …

Oncology drug development has benefited from the ability in many cases to directly measure
disease burden by clinical and radiographic measures. Tumor-based end points including …

Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Patients can be immunocompromised from a diverse range of disease and treatment factors,
including malignancies, autoimmune disorders and their treatments, and organ and stem …

Background Adding ibrutinib to standard immunochemotherapy might improve outcomes
and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or …